<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-17T04:28:21Z</responseDate><request verb="GetRecord" identifier="oai:www.recercat.cat:11351/5858" metadataPrefix="rdf">https://recercat.cat/oai/request</request><GetRecord><record><header><identifier>oai:recercat.cat:11351/5858</identifier><datestamp>2025-10-24T10:39:15Z</datestamp><setSpec>com_2072_378070</setSpec><setSpec>com_2072_378040</setSpec><setSpec>col_2072_378092</setSpec></header><metadata><rdf:RDF xmlns:rdf="http://www.openarchives.org/OAI/2.0/rdf/" xmlns:ow="http://www.ontoweb.org/ontology/1#" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:ds="http://dspace.org/ds/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/rdf/ http://www.openarchives.org/OAI/2.0/rdf.xsd">
   <ow:Publication rdf:about="oai:recercat.cat:11351/5858">
      <dc:title>Consensus on management of castration-resistant prostate cancer on behalf of the Urological Tumours Working Group (URONCOR) of the Spanish Society of Radiation Oncology</dc:title>
      <dc:creator>Gómez‑Caamaño, A.</dc:creator>
      <dc:creator>González‑San Segundo, C.</dc:creator>
      <dc:creator>Henríquez, I.</dc:creator>
      <dc:creator>Maldonado Pijoan, Javier</dc:creator>
      <dc:creator>Zapatero, A.</dc:creator>
      <dc:subject>Pròstata - Càncer - Tractament</dc:subject>
      <dc:subject>DISEASES::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms, Male::Prostatic Neoplasms::Prostatic Neoplasms, Castration-Resistant</dc:subject>
      <dc:subject>Other subheadings::Other subheadings::/therapy</dc:subject>
      <dc:subject>ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Clinical Decision-Making</dc:subject>
      <dc:subject>ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias de los genitales masculinos::neoplasias de la próstata::neoplasias prostáticas resistentes a la castración</dc:subject>
      <dc:subject>Otros calificadores::Otros calificadores::/terapia</dc:subject>
      <dc:subject>TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::toma de decisiones clínicas</dc:subject>
      <dc:description>Càncer de pròstata resistent a la castració; Oncologia de les radiacions; Consens</dc:description>
      <dc:description>Cáncer de próstata resistente a la castración; Oncología radioterápica; Consenso</dc:description>
      <dc:description>Castration-resistant prostate cancer; Radiation oncology; Consensus</dc:description>
      <dc:description>Background: The knowledge in the field of castration-resistant prostate cancer (CRPC) is developing rapidly, with emerging new therapies and advances in imaging. Nonetheless, in multiple areas there is still a lack of or very limited evidence, and clear guidance from clinicians regarding optimal strategy is required.&#xd;
&#xd;
Methods: A modified Delphi method, with 116 relevant questions divided into 7 different CRPC management topics, was used to develop a consensus statement by the URONCOR group.&#xd;
&#xd;
Results: A strong consensus or unanimity was reached on 93% of the proposed questions. The seven topics addressed were: CRPC definition, symptomatic patients, diagnosis of metastasis, CRPC progression, M0 management, M1 management and sequencing therapy, and treatment monitoring.&#xd;
&#xd;
Conclusions: The recommendations based on the radiation oncology experts' opinions are intended to provide cancer specialists with expert guidance and to standardise CRPC patient management in Spain, facilitating decision-making in different clinically relevant issues regarding CRPC patients.</dc:description>
      <dc:date>2025-10-24T10:39:15Z</dc:date>
      <dc:date>2025-10-24T10:39:15Z</dc:date>
      <dc:date>2021-04-15T07:38:14Z</dc:date>
      <dc:date>2021-04-15T07:38:14Z</dc:date>
      <dc:date>2019-04</dc:date>
      <dc:type>info:eu-repo/semantics/article</dc:type>
      <dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
      <dc:identifier>http://hdl.handle.net/11351/5858</dc:identifier>
      <dc:relation>Clinical and Translational Oncology;21(4)</dc:relation>
      <dc:relation>https://link.springer.com/article/10.1007%2Fs12094-018-1940-2</dc:relation>
      <dc:rights>Attribution 4.0 International</dc:rights>
      <dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
      <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
      <dc:publisher>Springer</dc:publisher>
      <dc:source>Scientia</dc:source>
   </ow:Publication>
</rdf:RDF></metadata></record></GetRecord></OAI-PMH>